----
Current ValuationThe current P/E ratio is -14.68, above the reasonable range, cheaper than 7.48% of the time in the past 1 years, and the industry ranks 201/256, the industry Median -1.14.
-14.68xP/E
$24.60Stock price
$-1.68Earnings per share
-14.68xP/E
Stock price$24.60Earnings per share$-1.68
Historical Valuation
P/E ratioTypical rangeMedian
- P/E ratio
- -16.07x
- Typical range
- -18.77x–-15.07x
Peer P/E ratio Comparison
It displays how the company's P/E ratio compares to top companies within its industry.
0285684112
The industry median valuation is currently at or below 0 and may not serve as a meaningful benchmark.
Industry P/E ratio Comparison
This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
0x20x40x60x80x100x
| Name/Symbol | |||
|---|---|---|---|
TAKUSTakeda Pharmaceutical Company | -59.31x | 154.63% | $61.95B |
BAYRYUSBayer | -23.64x | -- | $47.63B |
BAYZFUSBayer Aktiengesellschaft | -23.80x | -- | $47.94B |
VTRSUSViatris | -51.07x | 107.68% | $20.97B |
ELANUSElanco Animal Health | -58.98x | 129.36% | $11.74B |
VREOFUSVIREO GROWTH INC | -127.52x | -- | $8.56B |
AXSMUSAxsome Therap | -42.59x | 21.51% | $8.16B |
BLTEUSBelite Bio | -57.97x | 29.87% | $5.93B |
CURLFUSCuraleaf Holdings, Inc. | -112.26x | -- | $5.84B |
MANEUSVeraDermics | -48.99x | 97.44% | $5.11B |
RGCUSRegencell Bioscience | -425.53x | -- | $4.98B |
DFTXUSDefinium Therapeutics | -12.52x | 54.37% | $4.43B |
EWTXUSEdgewise Therapeutics | -20.88x | 207.38% | $4.12B |
AMLXUSAmylyx Pharmaceuticals | -22.55x | 1.76% | $3.43B |
TARSUSTarsus Pharmaceuticals | -65.62x | 201.10% | $3.05B |
ELVNUSEnliven Therapeutics | -26.77x | 5.59% | $2.84B |
MBXUSMBX Biosciences | -24.23x | 31.12% | $2.53B |
BHCUSBausch Health | -2.15x | 569.84% | $2.36B |
SUPNUSSupernus Pharma | -21.07x | 66.18% | $2.32B |
PRGOUSPerrigo | -1.29x | 100.10% | $2.23B |
Risk Warning
Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.
